Browse > Article

Antiangiogenic Effect of $As_4O_6$ on the Angiogenesis Induced by Vascular Endothelial Growth Factor (VEGF) in the Rat Cornea  

Kwon Do-hyoung (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Jang Jae young (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Yi Na-young (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Jeong Man-bok (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Park Shin-ae (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Kim Min-su (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Nam Tchi-chou (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Park Myung-jin (Laboratory of Cell Biology, Department of Neurosurgery, Korea Institute of Radiological and Medical Sciences, Seoul)
Bae Ill-ju (Laboratory of Chonjisan Institute, Seoul)
Rhee Chang-hun (Laboratory of Cell Biology, Department of Neurosurgery, Korea Institute of Radiological and Medical Sciences, Seoul)
Seo Kang-moon (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Publication Information
Journal of Veterinary Clinics / v.22, no.1, 2005 , pp. 16-20 More about this Journal
Abstract
The purpose of this study was to compare the antiangiogenic effects of As₄O/sub 6/ to those of As₂O₃ on the rat corneal micropocket model induced by VEGF. 20 ng VEGF impregnated pellets were used for angiogenic inducer on the rat cornea micropocket assay in this study. After ophthalmoscopic examination, Sprague-Dawley rats with normal cornea were implanted VEGF pellet. Total 60 eyes were used in this study. Control group only received VEGF pellet, As₂O₃ group followed oral administration of As₂O₃ at a dose of 50 mg/kg per day after VEGF pellet implantation and As₄O/sub 6/ group followed oral administration of As₄O/sub 6/ at a dose of 50 mg/kg per day after VEGF pellet implantation were classified. The eyes were examined under a surgical microscope daily on postoperative from day 3 to day 9 after pellet implantation. The number, length, clock hour of vascularization, and area of vessels in As₄O/sub 6/ group were significantly less evident than those of control group and As₂O₃ group (P < 0.05). In conclusion, As₄O/sub 6/ had better antiangiogenic effects on the new vessel induced by VEGF in the rat cornea.
Keywords
As₄O/sub 6/; As₂O₃; VEGF; antiangiogenesis; rat;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Munshi N. Arsenic trioxide : An emerging therapy of multiple myeloma. Oncologist 2001; 6: 17-21
2 Kim K, Li B, Winer J, Armanini M, Gillett N, Phillips H, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844   DOI   ScienceOn
3 Lew Y, Brown S, Griffin R, Song C, Kim J. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033-6037
4 Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY, Use of arsenic trioxde($As_2O_3$) in the treatment of acute promyelocytic leukemia(APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360
5 Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, Yi NY, Jeong MB, Jeong SM, Nam TC, Seo KM. Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. J Vet Med Sci 2004; 66: 1091-1095   DOI   ScienceOn
6 Jing Y, Dai J, Chalmers-Redman R. Tatton W, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111
7 Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674   DOI   PUBMED   ScienceOn
8 Lee JB, Jung SE, Lee HC, Kwon HM, Hong BK, Park HY, Kim EK, Oh JH. Effect of vascular endothelial growth factor(VEGF) on the corneal neovascularization and expression of MMP-2,9,TIMP-1,2 and flk-1. J Korean Ophthalmol Soc 2001; 42: 1053-1062
9 Jin YJ, Lien WH, Tsai WC, Yang GW, Li C, Wu LW. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 2001; 4: 313-321   DOI   ScienceOn
10 Kenyon B, Browne F, D'Amato R. Effect of thalidomide and related metabolites in a mouse corneal model of neocvascularization. Exp Eye Res 1997; 64: 971-978   DOI   ScienceOn
11 Waxman S, Anderson K. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6: 3-10
12 D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082-4085
13 Soignet S, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti L, Corso D, DeBlasio A, Garbrilove J, Scheinberg D, Pandolfi P, Warrell R. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. NEJM 1998; 339: 1341-1348   DOI   ScienceOn
14 Konig A, Wrazel L, Warrell Jr R, Rivi R, Pandolfi P, Jakubowski A, Gabrilove J, Comparative activity of melarsoprol an arsenic trioxide in chronic B-cell leukemia Lines. Blood 1997; 90: 562-570
15 Park CH. Angiogenic effect of vascular endothelial growth factor on the rat cornea. Kangwon national univerity. 2003
16 Roboz G, Dias S, Lam G, Lane W, Soignet S, Warrell Jr R, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530
17 University of Tennessee, Department of EHS. 1997. Arsenic trioxide. http://web.utk.edu/~ehss/arsenic/arsenicb.htm
18 Wilson H. Miller, Jr., Hyman M. Schipper, Janet S. Lee, Jack Singer, and Samuel Waxman. Mechanisms of action of arsenic trioxide. Cancer Research 2002; 62: 3893-3903
19 Antman K. Introduction : The history of arsenic trioxide in cancer therapy. Oncologist 2001; 6: 1-2
20 Kenyon B, Voest E, Chen C, Flynn E, Fokman J, D'Amato R. A Model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-1632
21 Fokman J, D'Amore P. Blood vessel formation : what is its molecular basis? Cell 1996; 87: 1153-1155   DOI   ScienceOn
22 Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. International Journal of Oncology 2003; 22: 1271-1276
23 Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, Vascular endothelial growth factor(VEGF) and its receptors. FASEB J 1999; 13: 9-18